For patients with symptomatic disease necessitating therapy, ibrutinib is often advised depending on four stage III randomized scientific trials comparing ibrutinib with chlorambucil monotherapy106 along with other usually applied CIT combinations, particularly FCR, bendamustine additionally rituxim